<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1510885" disease_type="Neoplastic Process" abbrv="">Angiogenic switch</z:e> marks the beginning of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>'s strategy to acquire independent blood supply </plain></SENT>
<SENT sid="1" pm="."><plain>In some subtypes of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, higher local vascular endothelial growth factor (VEGF) expression correlates with increased microvessel density </plain></SENT>
<SENT sid="2" pm="."><plain>However, this local VEGF expression is higher only in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with elevated expression of the receptors of the growth factor, suggesting an autocrine growth-promoting feedback loop </plain></SENT>
<SENT sid="3" pm="."><plain>Several studies have indicated that VEGF receptors are also targeted by Tat protein from the HIV-1-infected cells </plain></SENT>
<SENT sid="4" pm="."><plain>Given the similarity of the basic region of Tat to the angiogenic factors (basic fibroblast growth factor, VEGF), Tat mimics these proteins and binds to their receptors </plain></SENT>
<SENT sid="5" pm="."><plain>We evaluated the role of HIV-1 Tat in regulating the level of VEGF expression and microvessel density in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-related diffuse large B-cell (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>By luciferase assay, we showed that VEGF promoter activity was downregulated in vitro in cells transfected with Tat </plain></SENT>
<SENT sid="7" pm="."><plain>Reduced VEGF protein expression in primary HIV-1 positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, compared to the negative cases, supported the findings of promoter downregulation from the cell lines </plain></SENT>
<SENT sid="8" pm="."><plain>Microvascular density assessed by CD34 expression was, however, higher in HIV-1 positive than in HIV-1 negative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that Tat has a wider angiogenic role, besides the regulation of VEGF expression </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, targeting Tat protein itself and stabilizing transient silencing of VEGF expression or use of monoclonal antibodies against their receptors in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> will open a window for future explorable pathways in the management of angiogenic phenotypes in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>-associated non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>